Close
CDMO Safety Testing 2026
Novotech

Clinical research data sharing promises new cures and treatments

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Transforming the Future of Pharmaceutical Innovation

The pharmaceutical industry stands at the edge of a...

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

Decentralized Clinical Trials Market Advances Worldwide

The global Decentralized Clinical Trials Market is expected to...
- Advertisement -

Clinical research generates extensive amounts of data, yet most of it is siloed or generally unavailable to a larger pool of willing potential researchers.

If this data were liberated to the masses, we would venture into a world of endless possibilities where the search for new cures and treatments could be accelerated. From curing cancer to combating cardiovascular disease, clinical research data sharing has the potential to benefit many health care goals.

Clinical research data sharing for cardiovascular scientific discovery
The Duke Clinical Research Institute (DCRI) is at the forefront of this movement to engage in data sharing and research transparency, as noted by Drs. Eric Peterson and Michael Pencina in the short video below.

DCRI is the first academic institution to share their data with the general research community around the world, believing that better, faster and more innovative research will happen if academic institutions share their data.

The DCRI is releasing data from their Duke Databank for Cardiovascular disease. It contains de-identified patient records of more than 100,000 procedures on more than 50,000 patients. Approved researchers will have access to the data to test clinical hypothesis, develop clinical trial protocols and assess long term outcomes and trends.

“Researchers who have good questions can ask questions of that data, analyze it in a protected environment, and ultimately make discoveries that hopefully will help heart disease patients in the future,” says Peterson, in the video.

Results with clinical research data sharing
Secondary analysis of clinical trial research data has already yielded amazing results. For example, Project Datasphere, one of the initiatives of the CEO Roundtable on Cancer, was founded by former President George H.W. Bush who challenged the industry to be โ€œbold and venturesomeโ€ in the fight against cancer.

Project Datasphere paved the way to share, integrate and analyze collective cancer research data into one single location and currently contains data from 34,000 patients and a base of more than 1400 researchers accessing the data for new discovery.

So far 15 articles, abstracts and posters based on Project DataSphere data have been accepted by peer reviewed publications. No doubt, this is just the tip of the iceberg. Project Datasphere recognizes that the true power comes from increasing the volume of data about patients, and the group is actively working towards a 100,000-patient goal.

Through Project Datasphere and other programs, clinical trial data sharing is firmly entrenched in the pharmaceutical industry. It is our hope that other academic research institutions follow in the footsteps of the DCRI and Project Datasphere to overcome any internal challenges and liberate historical clinical research on a data sharing platform. We would welcome the opportunity to share our experiences of this voyage of discovery.

Learn how SAS plays a role in the Duke Databank for Cardiovascular Disease

Author: Patrick Homer

Author Image

Patrick Homer leads the Commercial Life Sciences practice at SAS, where he has been responsible for developing a number of advanced analytical applications, such as predictive modeling for physician segmentation, demand forecasting for inventory optimization, social media analytics, master data management for physician spending reporting, visualization of real world data, as well as launch sequence pricing optimization.

Prior to joining SAS, Homer spent 20 years working in the pharmaceutical industry, starting his career in sales, then progressing to running sales teams before moving into business development at Quintiles for sales outsourcing.Clinical research data sharing promises new cures and treatments.

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Transforming the Future of Pharmaceutical Innovation

The pharmaceutical industry stands at the edge of a...

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

Decentralized Clinical Trials Market Advances Worldwide

The global Decentralized Clinical Trials Market is expected to...

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป